MYGN vs PODD · rev $837.6M vs P/E 34, rev $1.56B
Myriad Genetics Inc (MYGN) versus Insulet Corporation (PODD) — a side-by-side from cached financials, not a winner call.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Latest reported MYGN revenue for 2024-12-31 was $837.6M. Net income was -$127.3M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. MYGN currently screens at market cap $413.7M.
Latest reported PODD revenue for 2026-06-30 was $1.56B. Net income was $186.1M. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
MYGN currently screens at market cap $413.7M. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
Not investment advice. Open the MYGN and PODD stock pages for the full models.
Not investment advice.